1. Home
  2. VERA vs FSK Comparison

VERA vs FSK Comparison

Compare VERA & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$30.01

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo FS KKR Capital Corp.

FSK

FS KKR Capital Corp.

HOLD

Current Price

$11.44

Market Cap

3.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERA
FSK
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.0B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
VERA
FSK
Price
$30.01
$11.44
Analyst Decision
Strong Buy
Hold
Analyst Count
10
8
Target Price
$81.30
$13.19
AVG Volume (30 Days)
2.0M
2.3M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
18.82%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$472.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.07
$9.72
52 Week High
$56.05
$20.41

Technical Indicators

Market Signals
Indicator
VERA
FSK
Relative Strength Index (RSI) N/A 59.40
Support Level N/A $10.41
Resistance Level N/A $11.22
Average True Range (ATR) 0.00 0.28
MACD 0.00 0.02
Stochastic Oscillator 0.00 99.60

Price Performance

Historical Comparison
VERA
FSK

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

Share on Social Networks: